VALGIMIGLI, Marco
VALGIMIGLI, Marco
Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial
2021 Landi, Antonio; Branca, Mattia; Andò, Giuseppe; Russo, Filippo; Frigoli, Enrico; Gargiulo, Giuseppe; Briguori, Carlo; Vranckx, Pascal; Leonardi, Sergio; Gragnano, Felice; Calabrò, Paolo; Campo, Gianluca; Ambrosio, Giuseppe; Santucci, Andrea; Varbella, Ferdinando; Zaro, Tiziana; Heg, Dik; Windecker, Stephan; Jüni, Peter; Pedrazzini, Giovanni; Valgimigli, Marco
CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure
file con accesso da definire2004 Valgimigli, Marco; Rigolin, Gian Matteo; Fucili, Alessandro; DELLA PORTA, M; Soukhomovskaia, Olga; Malagutti, Patrizia; Bugli, Anna Maria; ZENONE BRAGOTTI, Letizia; Francolini, G; Mauro, Endri; Castoldi, Gianluigi; Ferrari, Roberto
CD34+ cells mobilization in myocardial infarction: a link with heart failure?
file con accesso da definire2003 Rigolin, Gian Matteo; Della Porta, M; Valgimigli, Marco; Bugli, Am; Zenone Bragotti, L; Malagutti, Patrizia; Merlin, F; Campioni, Diana; Gardini, E; Macri, G; Ferrari, Roberto; Castoldi, G.
Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry
2021 Komajda, Michel; Cosentino, Francesco; Ferrari, Roberto; Laroche, Cécile; Maggioni, Aldo; Steg, Philippe Gabriel; Tavazzi, Luigi; Kerneis, Mathieu; Valgimigli, Marco; Gale, Chris P
Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial
2008 Valgimigli, M; Campo, Gianluca Calogero; Percoco, G; Bolognese, L; Vassanelli, C; Colangelo, S; de Cesare, N; Rodriguez, Ae; Ferrario, M; Moreno, R; Piva, T; Sheiban, I; Pasquetto, G; Prati, F; Nazzaro, Ms; Parrinello, G; Ferrari, Roberto
Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial
2018 Schur, Nadine; Brugaletta, Salvatore; Cequier, Angel; Iñiguez, Andrés; Serra, Antonio; Jiménez-Quevedo, Pilar; Mainar, Vicente; Campo, Gianluca; Tespili, Maurizio; Heijer, Peter den; Bethencourt, Armando; Vazquez, Nicolás; Valgimigli, Marco; Serruys, Patrick W.; Ademi, Zanfina; Schwenkglenks, Matthias; Sabaté, Manel
Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention? Insights From the EXAMINATION Trial
2019 Costa, F.; Brugaletta, S.; Pernigotti, A.; Flores-Ulmanzor, E.; Ortega-Paz, L.; Cequier, A.; Iniguez, A.; Serra, A.; Jimenez-Quevedo, P.; Mainar, V.; Campo, G.; Tespili, M.; den Heijer, P.; Bethencourt, A.; Vazquez, N.; van Es, G. A.; Backx, B.; Valgimigli, M.; Serruys, P.; Sabate, M.
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
2021 Valgimigli, M.; Cao, D.; Angiolillo, D. J.; Bangalore, S.; Bhatt, D. L.; Ge, J.; Hermiller, J.; Makkar, R. R.; Neumann, F. -J.; Saito, S.; Picon, H.; Toelg, R.; Maksoud, A.; Chehab, B. M.; Choi, J. W.; Campo, G.; De la Torre Hernandez, J. M.; Kunadian, V.; Sardella, G.; Thiele, H.; Varenne, O.; Vranckx, P.; Windecker, S.; Zhou, Y.; Krucoff, M. W.; Ruster, K.; Zheng, Y.; Mehran, R.
Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention
file con accesso da definire2013 Biscaglia, S.; Tebaldi, M.; Vranckx, P.; Campo, G.; Valgimigli, M.
Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress
file con accesso da definire2003 Valgimigli, Marco; Merli, E; Malagutti, Patrizia; Soukhomovskaia, O; Cicchitelli, G; Macri, G; Ferrari, Roberto
EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)
2016 Komajda, M; Weidinger, F; Kerneis, M; Cosentino, F; Cremonesi, A; Ferrari, Roberto; Kownator, S; Steg, Pg; Tavazzi, Luigi; Valgimigli, Marco; Szwed, H; Majda, W; Olivari, Z; Van Belle, E; Shlyakhto, Ev; Mintale, I; Slapikas, R; Rittger, H; Mendes, M; Tsioufis, C; Balanescu, S; Laroche, C; Maggioni, Aldo Pietro
Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale: The FABOLUS FASTER Trial
2021 Gargiulo, G.; Esposito, G.; Cirillo, P.; Nagler, M.; Minuz, P.; Campo, G.; Gragnano, F.; Manavifar, N.; Piccolo, R.; Avvedimento, M.; Tebaldi, M.; Wahl, A.; Hunziker, L.; Billinger, M.; Heg, D.; Windecker, S.; Valgimigli, M.
Factor XIIIA V34L and Factor XIIIB H95R Gene Polymorphisms: Effects on the Risk of Myocardial Infarction and on Survival.
file con accesso da definire2006 Gemmati, Donato; Catozzi, Linda; Campo, Gianluca Calogero; Tognazzo, Silvia; Federici, Federica; Serino, Maria Luisa; Valgimigli, Marco; Malagutti, Patrizia; Carrescia, C; Guardagli, G; Bernardi, Francesco; Ferrari, Roberto; Scapoli, Gian Luigi
Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients.
file con accesso da definire2007 Gemmati, Donato; Federici, Federica; Campo, Gianluca Calogero; Tognazzo, Silvia; Serino, Maria Luisa; DE MATTEI, Monica; Valgimigli, Marco; Malagutti, Patrizia; Guardigli, Gabriele; Ferraresi, Paolo; Bernardi, Francesco; Ferrari, Roberto; Scapoli, Gian Luigi; Catozzi, Linda
High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients
file con accesso da definire2004 Valgimigli, Marco; Percoco, G; Cicchitelli, G; Ferrari, F; Barbieri, D; Ansani, L; Guardigli, G; Parrinello, G; Malagutti, Patrizia; Soukhomovskaia, O; Bettini, A; Campo, Gianluca Calogero; Ferrari, Roberto
Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction
file con accesso da definire2004 Valgimigli, Marco; Merli, Elisa; Malagutti, Patrizia; Soukhomovskaia, O; Cicchitelli, G; Antelli, A; Canistro, D; Francolini, G; Macri, G; Mastrorilli, F; Paolini, M; Ferrari, Roberto
Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates
2019 Gargiulo, Giuseppe; Patialiakas, Athanasios; Piccolo, Raffaele; Thury, Attila; Colangelo, Salvatore; Campo, Gianluca; Tebaldi, Matteo; Ungi, Imre; Tondi, Stefano; Roffi, Marco; Menozzi, Alberto; de Cesare, Nicoletta; Garbo, Roberto; Meliga, Emanuele; Testa, Luca; Gabriel, Henrique Mesquita; Ferlini, Marco; Liistro, Francesco; Dellavalle, Antonio; Vranckx, Pascal; Briguori, Carlo; Windecker, Stephan; Valgimigli, Marco
Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial
file con accesso da definire2015 Crimi, G.; Leonardi, S.; Costa, F.; Ariotti, S.; Tebaldi, M.; Biscaglia, S.; Valgimigli, M.
Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study
2009 Valgimigli, M; Campo, Gianluca Calogero; de Cesare, N; Meliga, E; Vranckx, P; Furgieri, A; Angiolillo, Dj; Sabatè, M; Hamon, M; Repetto, A; Colangelo, S; Brugaletta, S; Parrinello, G; Percoco, G; Ferrari, Roberto
Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy
2010 Campo, Gianluca Calogero; Fileti, L; de Cesare, N; Meliga, E; Furgieri, A; Russo, F; Colangelo, S; Brugaletta, S; Ferrari, Roberto; Valgimigli, M.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial | 2021 | Landi, Antonio; Branca, Mattia; Andò, Giuseppe; Russo, Filippo; Frigoli, Enrico; Gargiulo, Giusep...pe; Briguori, Carlo; Vranckx, Pascal; Leonardi, Sergio; Gragnano, Felice; Calabrò, Paolo; Campo, Gianluca; Ambrosio, Giuseppe; Santucci, Andrea; Varbella, Ferdinando; Zaro, Tiziana; Heg, Dik; Windecker, Stephan; Jüni, Peter; Pedrazzini, Giovanni; Valgimigli, Marco | |
| CD34+ and endothelial progenitor cells in patients with various degrees of congestive heart failure | 2004 | Valgimigli, Marco; Rigolin, Gian Matteo; Fucili, Alessandro; DELLA PORTA, M; Soukhomovskaia, Olga...; Malagutti, Patrizia; Bugli, Anna Maria; ZENONE BRAGOTTI, Letizia; Francolini, G; Mauro, Endri; Castoldi, Gianluigi; Ferrari, Roberto | file con accesso da definire |
| CD34+ cells mobilization in myocardial infarction: a link with heart failure? | 2003 | Rigolin, Gian Matteo; Della Porta, M; Valgimigli, Marco; Bugli, Am; Zenone Bragotti, L; Malagutti..., Patrizia; Merlin, F; Campioni, Diana; Gardini, E; Macri, G; Ferrari, Roberto; Castoldi, G. | file con accesso da definire |
| Cohort profile The ESC-EORP Chronic Ischemic Cardiovascular Disease Long-Term (CICD LT) registry | 2021 | Komajda, Michel; Cosentino, Francesco; Ferrari, Roberto; Laroche, Cécile; Maggioni, Aldo; Steg, P...hilippe Gabriel; Tavazzi, Luigi; Kerneis, Mathieu; Valgimigli, Marco; Gale, Chris P | |
| Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial | 2008 | Valgimigli, M; Campo, Gianluca Calogero; Percoco, G; Bolognese, L; Vassanelli, C; Colangelo, S; d...e Cesare, N; Rodriguez, Ae; Ferrario, M; Moreno, R; Piva, T; Sheiban, I; Pasquetto, G; Prati, F; Nazzaro, Ms; Parrinello, G; Ferrari, Roberto | |
| Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial | 2018 | Schur, Nadine; Brugaletta, Salvatore; Cequier, Angel; Iñiguez, Andrés; Serra, Antonio; Jiménez-Qu...evedo, Pilar; Mainar, Vicente; Campo, Gianluca; Tespili, Maurizio; Heijer, Peter den; Bethencourt, Armando; Vazquez, Nicolás; Valgimigli, Marco; Serruys, Patrick W.; Ademi, Zanfina; Schwenkglenks, Matthias; Sabaté, Manel | |
| Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention? Insights From the EXAMINATION Trial | 2019 | Costa, F.; Brugaletta, S.; Pernigotti, A.; Flores-Ulmanzor, E.; Ortega-Paz, L.; Cequier, A.; Inig...uez, A.; Serra, A.; Jimenez-Quevedo, P.; Mainar, V.; Campo, G.; Tespili, M.; den Heijer, P.; Bethencourt, A.; Vazquez, N.; van Es, G. A.; Backx, B.; Valgimigli, M.; Serruys, P.; Sabate, M. | |
| Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI | 2021 | Valgimigli, M.; Cao, D.; Angiolillo, D. J.; Bangalore, S.; Bhatt, D. L.; Ge, J.; Hermiller, J.; M...akkar, R. R.; Neumann, F. -J.; Saito, S.; Picon, H.; Toelg, R.; Maksoud, A.; Chehab, B. M.; Choi, J. W.; Campo, G.; De la Torre Hernandez, J. M.; Kunadian, V.; Sardella, G.; Thiele, H.; Varenne, O.; Vranckx, P.; Windecker, S.; Zhou, Y.; Krucoff, M. W.; Ruster, K.; Zheng, Y.; Mehran, R. | |
| Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention | 2013 | Biscaglia, S.; Tebaldi, M.; Vranckx, P.; Campo, G.; Valgimigli, M. | file con accesso da definire |
| Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress | 2003 | Valgimigli, Marco; Merli, E; Malagutti, Patrizia; Soukhomovskaia, O; Cicchitelli, G; Macri, G; Fe...rrari, Roberto | file con accesso da definire |
| EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT) | 2016 | Komajda, M; Weidinger, F; Kerneis, M; Cosentino, F; Cremonesi, A; Ferrari, Roberto; Kownator, S; ...Steg, Pg; Tavazzi, Luigi; Valgimigli, Marco; Szwed, H; Majda, W; Olivari, Z; Van Belle, E; Shlyakhto, Ev; Mintale, I; Slapikas, R; Rittger, H; Mendes, M; Tsioufis, C; Balanescu, S; Laroche, C; Maggioni, Aldo Pietro | |
| Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale: The FABOLUS FASTER Trial | 2021 | Gargiulo, G.; Esposito, G.; Cirillo, P.; Nagler, M.; Minuz, P.; Campo, G.; Gragnano, F.; Manavifa...r, N.; Piccolo, R.; Avvedimento, M.; Tebaldi, M.; Wahl, A.; Hunziker, L.; Billinger, M.; Heg, D.; Windecker, S.; Valgimigli, M. | |
| Factor XIIIA V34L and Factor XIIIB H95R Gene Polymorphisms: Effects on the Risk of Myocardial Infarction and on Survival. | 2006 | Gemmati, Donato; Catozzi, Linda; Campo, Gianluca Calogero; Tognazzo, Silvia; Federici, Federica; ...Serino, Maria Luisa; Valgimigli, Marco; Malagutti, Patrizia; Carrescia, C; Guardagli, G; Bernardi, Francesco; Ferrari, Roberto; Scapoli, Gian Luigi | file con accesso da definire |
| Factor XIIIA-V34L and factor XIIIB-H95R gene variants: effects on survival in myocardial infarction patients. | 2007 | Gemmati, Donato; Federici, Federica; Campo, Gianluca Calogero; Tognazzo, Silvia; Serino, Maria Lu...isa; DE MATTEI, Monica; Valgimigli, Marco; Malagutti, Patrizia; Guardigli, Gabriele; Ferraresi, Paolo; Bernardi, Francesco; Ferrari, Roberto; Scapoli, Gian Luigi; Catozzi, Linda | file con accesso da definire |
| High-dose BoluS TiRofibAn and Sirolimus eluting STEnt versus abiciximab and bare metal stent in acute MYocardial infarction (STRATEGY) study - Protocol design and demography of the first 100 patients | 2004 | Valgimigli, Marco; Percoco, G; Cicchitelli, G; Ferrari, F; Barbieri, D; Ansani, L; Guardigli, G; ...Parrinello, G; Malagutti, Patrizia; Soukhomovskaia, O; Bettini, A; Campo, Gianluca Calogero; Ferrari, Roberto | file con accesso da definire |
| Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction | 2004 | Valgimigli, Marco; Merli, Elisa; Malagutti, Patrizia; Soukhomovskaia, O; Cicchitelli, G; Antelli,... A; Canistro, D; Francolini, G; Macri, G; Mastrorilli, F; Paolini, M; Ferrari, Roberto | file con accesso da definire |
| Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates | 2019 | Gargiulo, Giuseppe; Patialiakas, Athanasios; Piccolo, Raffaele; Thury, Attila; Colangelo, Salvato...re; Campo, Gianluca; Tebaldi, Matteo; Ungi, Imre; Tondi, Stefano; Roffi, Marco; Menozzi, Alberto; de Cesare, Nicoletta; Garbo, Roberto; Meliga, Emanuele; Testa, Luca; Gabriel, Henrique Mesquita; Ferlini, Marco; Liistro, Francesco; Dellavalle, Antonio; Vranckx, Pascal; Briguori, Carlo; Windecker, Stephan; Valgimigli, Marco | |
| Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer PRODIGY trial | 2015 | Crimi, G.; Leonardi, S.; Costa, F.; Ariotti, S.; Tebaldi, M.; Biscaglia, S.; Valgimigli, M. | file con accesso da definire |
| Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study | 2009 | Valgimigli, M; Campo, Gianluca Calogero; de Cesare, N; Meliga, E; Vranckx, P; Furgieri, A; Angiol...illo, Dj; Sabatè, M; Hamon, M; Repetto, A; Colangelo, S; Brugaletta, S; Parrinello, G; Percoco, G; Ferrari, Roberto | |
| Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy | 2010 | Campo, Gianluca Calogero; Fileti, L; de Cesare, N; Meliga, E; Furgieri, A; Russo, F; Colangelo, S...; Brugaletta, S; Ferrari, Roberto; Valgimigli, M. |